MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the appointment of Rita Johnson-Greene as Chief Financial Officer (CFO). “Mrs. Johnson-Greene’s diverse background across a variety of strategic roles at organizations representing many facets of the industry make her well-suited to serve as Ocugen’s CFO,” said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Oc ...

Core Viewpoint - Ocugen, Inc. has successfully closed an underwritten registered direct offering of 15 million shares at $1.50 per share, resulting in net proceeds of $20.85 million, aimed at supporting its operations and extending its cash runway into Q4 2026 [1][2]. Group 1: Offering Details - The offering consisted of 15,000,000 shares priced at $1.50 each, leading to net proceeds of $20.85 million after expenses [1]. - The financing was led by RTW Investments, with participation from both new and existing investors [1]. - Oppenheimer & Co. served as the sole book-running manager for the offering [2]. Group 2: Use of Proceeds - The net proceeds will be allocated for general corporate purposes, capital expenditures, working capital, and administrative expenses [2]. - The funding is expected to extend the company's cash runway into the fourth quarter of 2026 [2]. Group 3: Company Overview - Ocugen, Inc. is a biotechnology leader focused on gene therapies for blindness diseases, utilizing a modifier gene therapy platform to address complex diseases caused by multiple gene network imbalances [5]. - The company is developing programs for inherited retinal diseases and blindness conditions affecting millions globally, including retinitis pigmentosa, Stargardt disease, and geographic atrophy [5].

Core Viewpoint - Ocugen Inc announced a $22.5 million underwritten offering of common stock, leading to a significant decline in its share price due to dilution fears and market concerns about its financial outlook [1][4]. Group 1: Stock Offering Details - The company is issuing 15 million new shares at a price of $1.50 each, with the proceeds intended for general corporate purposes, capital spending, and working capital [2]. - The pricing of the offering at $1.50 suggests that institutional buyers may have required a discount, which could reset market expectations for the stock's near-term value [3]. Group 2: Market Reaction and Implications - Equity offerings typically exert downward pressure on share prices as they dilute existing investors' ownership, leading to reduced potential earnings per share [3]. - The offering, while strengthening Ocugen's balance sheet and supporting its gene therapy development, highlights the company's reliance on capital markets for funding, which can increase perceived risk in a volatile biotech environment [4]. - Following the announcement, Ocugen shares fell by 10.48%, trading at $1.49 at the time of publication [5].

Core Viewpoint - Ocugen, Inc. has announced the pricing of an underwritten offering of 15 million shares of common stock at $1.50 per share, aiming for gross proceeds of $22.5 million, expected to close around January 22, 2026 [1]. Group 1: Offering Details - The offering consists of 15,000,000 shares priced at $1.50 each, resulting in gross proceeds of $22.5 million before expenses [1]. - The offering is led by RTW Investments, with participation from both new and existing investors [1]. - Oppenheimer & Co. is the sole book-running manager for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for general corporate purposes, capital expenditures, working capital, and general and administrative expenses [2]. Group 3: Company Overview - Ocugen, Inc. is a biotechnology leader focused on gene therapies for blindness diseases, with a modifier gene therapy platform aimed at addressing significant unmet medical needs [5]. - The company is developing programs for inherited retinal diseases and blindness diseases, including retinitis pigmentosa, Stargardt disease, and geographic atrophy [5].

Group 1 - The article promotes a weekly newsletter focused on stocks in the biotech, pharma, and healthcare industries, highlighting key trends and catalysts that influence market valuations [1] - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the Haggerston BioHealth investing group, which caters to both novice and experienced investors [1] - The investing group provides insights such as buy and sell ratings, product sales forecasts, integrated financial statements, discounted cash flow analysis, and market-by-market analysis for major pharmaceutical companies [1]

Core Viewpoint - Ocugen is discussing data from the first half of patients who have completed one year since treatment in the OCU410 Phase II ArMaDa clinical trial for geographic atrophy [1] Group 1: Company Overview - The webcast features key executives including Dr. Shankar Musunuri (Chairman, CEO, and Co-Founder), Dr. Huma Qamar (Chief Medical Officer), and Dr. Arun Upadhyay (Chief Scientific Officer) [1] - Distinguished clinical trial investigators are also participating in the discussion, including Dr. Jay Chhablani, Dr. Arshad Khanani, and Dr. Lejla Vajzovic [1] Group 2: Clinical Trial Insights - The focus of the webcast is on the clinical trial data related to the OCU410 treatment for geographic atrophy, highlighting the significance of the one-year patient data [1]

Core Insights - Ocugen, Inc. has shared preliminary data from its Phase 2 clinical trial for OCU410, a gene therapy targeting geographic atrophy, showing promising results [1][3] Clinical Trial Results - The Phase 2 ArMaDa clinical trial indicated a 46% reduction in lesion growth compared to the control group after 12 months, with no serious adverse events reported [3] - The medium dose of OCU410 achieved a 54% reduction in lesion size, while the high dose showed a 36% reduction, highlighting the therapy's potential efficacy [3] Future Plans - The company plans to report full data from the Phase 2 trial later this quarter and initiate a Phase 3 trial in 2026 [4] - Ocugen is on track for a Biologics License Application (BLA) filing for OCU410 in 2028 [4] Other Programs - Ocugen announced the publication of Phase 1 GARDian1 trial results for OCU410ST, a novel modifier gene therapy for Stargardt disease, in the peer-reviewed journal Nature Eye [5] - The Phase 1 GARDian1 trial demonstrated robust efficacy and safety outcomes supporting the clinical development of OCU410ST [6] - In September 2025, Ocugen entered a licensing agreement with Kwangdong Pharmaceutical for the exclusive Korean rights to OCU400, its modifier gene therapy for retinitis pigmentosa [6] Stock Performance - Ocugen shares were down 9.08% at $1.71 at the time of publication, despite the broader market gains [2][9] - The stock is currently trading 15.2% above its 20-day simple moving average (SMA) and 28% above its 50-day SMA, indicating short-term strength [7] - Over the past 12 months, shares have increased 138.56% and are closer to their 52-week highs than lows [7]

Summary of Ocugen's OCU410 Phase 2 ARMADA Clinical Trial Conference Call Company and Industry Overview - **Company**: Ocugen - **Industry**: Biotechnology, specifically focusing on gene therapy for geographic atrophy (GA), a form of age-related macular degeneration (AMD) Key Points and Arguments Clinical Updates - The conference call provided updates on the OCU410 program, focusing on the phase 2 ARMADA trial and new data from phase 1 [2][3] - OCU410 is a gene therapy designed to address multiple pathways involved in GA through a single subretinal injection, contrasting with existing therapies that require frequent injections [5][30] Unmet Medical Need - Approximately 2 to 3 million patients in the U.S. and Europe suffer from GA, highlighting a significant unmet medical need [4] - Recent approvals of therapies like Syfovre and Izervay have not fully addressed the disease, as they target only one of the four major pathways involved in GA progression [4] OCU410's Mechanism of Action - OCU410 targets RORA, a nuclear receptor that regulates multiple pathways in retinal cells, providing four therapeutic benefits: 1. Anti-drusen activity, reducing drusen burden [8] 2. Anti-oxidative protection, enhancing retinal cell defenses against oxidative stress [9] 3. Anti-inflammatory modulation, suppressing harmful inflammation [9] 4. Anti-complement activity, preventing complement-mediated cell death [9] Phase 1 Trial Results - The phase 1 trial demonstrated a 20.2% reduction in GA lesion growth at 12 months compared to untreated eyes [15] - Preservation of photoreceptor structure was observed, with a 60% slower loss of the ellipsoid zone in treated eyes [17] Phase 2 Trial Design and Results - The phase 2 trial enrolled 51 patients, with a randomized control design [20] - OCU410 treatment resulted in a 46% statistically significant reduction in GA lesion growth compared to control eyes, with a P-value of 0.015 [24] - The medium dose group showed a 54% reduction in lesion growth, while the high-dose group showed a 36% reduction [25] Comparison with Approved Therapies - OCU410's 46% reduction in lesion growth at 12 months is significantly higher than the approximately 22% reduction seen with approved therapies at 24 months [27][28] - Up to 50% of treated patients achieved greater than 50% lesion size reduction compared to control [29] Safety Profile - OCU410 demonstrated a favorable safety profile with no serious adverse events reported [30] - The one-time administration of OCU410 eliminates the cumulative risks associated with frequent injections required by current therapies [23] Market Potential - OCU410 addresses a massive unmet medical need with the potential for a one-time definitive treatment, contrasting with the ongoing treatment burden of current therapies [31] Other Important Content - The call included insights from clinical trial investigators emphasizing the importance of the ellipsoid zone as a biomarker for photoreceptor health and its correlation with functional vision [40][74] - Future milestones include the full data set release and initiation of the phase 3 trial anticipated in 2026 [43][88] This summary encapsulates the critical aspects of Ocugen's OCU410 program and its potential impact on the treatment landscape for geographic atrophy.

Core Insights - Ocugen, Inc. announced positive preliminary 12-month data from the Phase 2 ArMaDa clinical trial for OCU410, a gene therapy for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD) [1][4] - The global prevalence of dAMD is 266 million, with GA affecting approximately 2-3 million people in the U.S. and Europe [1][8] Clinical Trial Findings - Phase 2 results show a 46% reduction in lesion growth compared to control, with a 50% responder rate achieving over 50% lesion size reduction [5][6] - No serious adverse events related to OCU410 were reported in both Phase 1 and Phase 2 trials [2][5] - The medium dose achieved a 54% lesion reduction, while the high dose achieved a 36% reduction compared to control [6] Treatment Landscape - Current treatment options for dAMD in the U.S. are limited and involve frequent injections with side effects, leaving approximately 2 million patients in Europe without approved treatments [2][8] - OCU410 is a multifunctional gene therapy targeting multiple pathways associated with GA, contrasting with existing therapies that target a single mechanism [3][9] Future Developments - Ocugen plans to file a Biologics License Application (BLA) for OCU410 in 2028, aiming for three regulatory submissions for marketing authorization within three years [7][10] - Full data from the Phase 2 clinical trial is expected to be reported later this quarter, with Phase 3 trials anticipated to begin in 2026 [4][7]

Core Insights - Ocugen, Inc. is hosting a conference call and live webcast to discuss data from the OCU410 Phase 2 ArMaDa clinical trial, focusing on patients who have completed one year since treatment [1] - The conference call is scheduled for January 15, 2026, at 8:30 a.m. ET, featuring key opinion leaders and Ocugen's executive leadership [1][2] Company Overview - Ocugen, Inc. is a biotechnology leader specializing in gene therapies for blindness diseases, utilizing a modifier gene therapy platform that addresses complex diseases caused by imbalances in multiple gene networks [3] - The company is developing therapies for inherited retinal diseases and blindness diseases, including retinitis pigmentosa, Stargardt disease, and geographic atrophy, which affect millions globally [3]